A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma
100 项与 BTK x CRBN x IKZF1 x IKZF3 x mTORC1 x mTORC2 相关的临床结果
100 项与 BTK x CRBN x IKZF1 x IKZF3 x mTORC1 x mTORC2 相关的转化医学
0 项与 BTK x CRBN x IKZF1 x IKZF3 x mTORC1 x mTORC2 相关的专利(医药)